Becton, Dickinson and Company (BDX)
Market Cap | 53.11B |
Revenue (ttm) | 20.87B |
Net Income (ttm) | 1.50B |
Shares Out | 286.61M |
EPS (ttm) | 5.16 |
PE Ratio | 35.90 |
Forward PE | 13.10 |
Dividend | $4.16 (2.24%) |
Ex-Dividend Date | Sep 8, 2025 |
Volume | 1,875,314 |
Open | 184.35 |
Previous Close | 183.63 |
Day's Range | 183.42 - 185.92 |
52-Week Range | 163.33 - 251.99 |
Beta | 0.28 |
Analysts | Buy |
Price Target | 231.50 (+24.92%) |
Earnings Date | Aug 7, 2025 |
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system... [Read more]
Financial Performance
In 2024, BDX's revenue was $20.18 billion, an increase of 4.16% compared to the previous year's $19.37 billion. Earnings were $1.71 billion, an increase of 19.73%.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for BDX stock is "Buy." The 12-month stock price target is $231.5, which is an increase of 24.92% from the latest price.
News

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
FRANKLIN LAKES, N.J. , July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination produ...

BD Board Declares Dividend
FRANKLIN LAKES, N.J. , July 22, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has decla...

WATERS CORPORATION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Waters Corporation - WAT
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger o...

Becton Dickinson gets its spinoff deal, but the stock is still falling
Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 billion of the proceeds to buy back stock.

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to ...

BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment
FRANKLIN LAKES, N.J. , July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin ha...

Best Dividend Aristocrats For July 2025
Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising pa...
New vaccine panel meeting underway
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on vaccines.

Becton Dickinson Stock (BDX): Why It's Best To Avoid For Now
Shares of Becton Dickinson and Company BDX are currently in its 17th phase of the 18-phase Adhishthana Cycle, and signs point toward continued underperformance and consolidation, likely lasting until ...

Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Becton, Dickinson and Company (NYSE:BDX) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 2:00 PM ET Company Participants Thomas E. Polen - President, CEO & Chairman Conference Cal...

Becton, Dickinson: A Dividend King Facing Challenges Offers Value
Becton, Dickinson is significantly undervalued, trading at 12.3x earnings with a 2.5% dividend yield, the highest in a decade. The company boasts a 53-year streak of dividend growth, excellent dividen...

June's Top Dividend Aristocrat Fat Pitches: Blue-Chip Bargains You Can't Miss
Despite bubble fears, 91% of market gains since 2009 are justified by fundamentals like earnings, dividends, and strong balance sheets. Stocks appear overvalued at face value, but strong long-term ear...

June's Dividend Kings: 3 Ideal Buys In 25 "Safer" Dogs
Most Dividend Kings are currently overpriced, but six offer fair value where annual dividends from $1,000 invested exceed their share price. Three top-yield Dividend Kings—Altria, Northwest Natural, a...

BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
FRANKLIN LAKES, N.J. , May 28, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data regist...

Best Dividend Aristocrats For June 2025
Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 20...

BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference
FRANKLIN LAKES, N.J. , May 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Goldman Sac...

Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'
FRANKLIN LAKES, N.J. , May 21, 2025 /PRNewswire/ -- First-of-their-kind studies published in The Lancet Oncology 1 and Cancer Medicine 2 provide new data showing that cancer patients in both hospital ...

35 Barron's Pro-Picks: One Ideal May DiviDog
Barron's interviewed eleven financial industry Roundtable-pros who tapped 65 predictions. Six non-ADR foreign-stocks and four mutual funds were dropped by YCharts screens of active US listings, leavin...

Becton, Dickinson and Company (BDX) Bank of America Securities Health Care Conference - (Transcript)
Becton, Dickinson and Company (NYSE:BDX) Bank of America Securities Health Care Conference Call May 13, 2025 1:00 PM ET Company Participants Tom Polen - Chairman, Chief Executive Officer and Presiden...

BD to Announce Financial Results for its Third Quarter of Fiscal 2025
FRANKLIN LAKES, N.J. , May 12, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio w...

The Best Health Care Stocks to Buy
The best health care stocks offer investors a defensive hedge in an uncertain market. Here's how to find them.

Buy 3 "Safer" Dividend Kings Of 25 From May's 55
The May collection of Dividend Kings grew to 55, with Automatic Data Processing and RLI Corporation joining, despite two companies dropping off for not increasing dividends. Six top-yield Dividend Kin...

Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years
Becton Dickinson, and Company BDX lowered its fiscal year 2025 guidance and provided an estimated tariff impact on Thursday.